Autobio Diagnostics (603658) Stock Overview
Engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
603658 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Autobio Diagnostics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥40.57 |
| 52 Week High | CN¥52.98 |
| 52 Week Low | CN¥36.49 |
| Beta | -0.12 |
| 1 Month Change | 0.62% |
| 3 Month Change | 3.92% |
| 1 Year Change | -0.66% |
| 3 Year Change | -14.23% |
| 5 Year Change | -66.56% |
| Change since IPO | 151.15% |
Recent News & Updates
Recent updates
Autobio Diagnostics Co., Ltd.'s (SHSE:603658) Price Is Right But Growth Is Lacking
Mar 10
Does Autobio Diagnostics (SHSE:603658) Have A Healthy Balance Sheet?
Dec 20Autobio Diagnostics Co., Ltd.'s (SHSE:603658) Prospects Need A Boost To Lift Shares
Nov 24Autobio Diagnostics Co., Ltd. (SHSE:603658) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 09Improved Earnings Required Before Autobio Diagnostics Co., Ltd. (SHSE:603658) Shares Find Their Feet
Jul 18Does Autobio Diagnostics (SHSE:603658) Have A Healthy Balance Sheet?
May 21Autobio Diagnostics Co., Ltd.'s (SHSE:603658) 27% Price Boost Is Out Of Tune With Earnings
Feb 27Shareholder Returns
| 603658 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -3.3% | -1.3% | 3.0% |
| 1Y | -0.7% | 25.2% | 50.6% |
Return vs Industry: 603658 underperformed the CN Medical Equipment industry which returned 25.2% over the past year.
Return vs Market: 603658 underperformed the CN Market which returned 50.6% over the past year.
Price Volatility
| 603658 volatility | |
|---|---|
| 603658 Average Weekly Movement | 2.4% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 603658 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603658's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 5,773 | Zeng Li Yang | www.autobio.com.cn |
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an automatic immunoassay analyzer; AutoLumo A2000 Plus, an automated chemiluminescence immunoassay analyzer; PHOmo microplate readers; LUmo microplate luminometers; and iWO and iWO-960 microplate washers.
Autobio Diagnostics Co., Ltd. Fundamentals Summary
| 603658 fundamental statistics | |
|---|---|
| Market cap | CN¥23.18b |
| Earnings (TTM) | CN¥1.15b |
| Revenue (TTM) | CN¥4.32b |
Is 603658 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603658 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.32b |
| Cost of Revenue | CN¥1.57b |
| Gross Profit | CN¥2.76b |
| Other Expenses | CN¥1.61b |
| Earnings | CN¥1.15b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.01 |
| Gross Margin | 63.77% |
| Net Profit Margin | 26.50% |
| Debt/Equity Ratio | 1.4% |
How did 603658 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/29 16:46 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Autobio Diagnostics Co., Ltd. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhe Sun | BofA Global Research |
| Zhe Sun | BofA Global Research |
| Pei Cheng | China Galaxy Securities Co., Ltd. |